Table 1.
n (%) | |
Median age (years) at diagnosis (range) | 60.8 (18.2–83.9) |
Caucasian race | 134 (71.3) |
Male gender | 123 (65.4) |
Biopsy site | |
Kidney | 71 (38.8) |
Metastasis | 92 (48.9) |
Kidney and metastasis | 20 (10.6) |
Not done/unknown | 5 (2.7) |
Clear cell histologya | 114 (60.6) |
Renal cell carcinoma (not otherwise specified) | 30 (16.0) |
Nonclear cell histology | 25 (13.3) |
Unclassified | 19 (10.1) |
Sarcomatoid dedifferentiationa | 16 (8.5) |
Bilateral tumor | 10 (5.3) |
ECOG PS | |
0 | 16 (8.5) |
1 | 106 (56.4) |
2 | 40 (21.3) |
3 | 26 (13.8) |
Clinical T stage | |
T1a | 16 (8.5) |
T1b | 29 (15.4) |
T2 | 28 (14.9) |
T3a | 36 (19.2) |
T3b | 52 (27.7) |
T3c | 1 (0.5) |
T4 | 26 (13.8) |
Number of visceral/bone metastasis | |
1 | 68 (36.2) |
2 | 73 (38.8) |
3 or more | 47 (25.0) |
Metastatic site | |
Lung | 128 (68.1) |
Bone | 83 (44.2) |
Liver | 58 (30.9) |
Adrenal | 44 (23.4) |
Brain | 22 (11.7) |
Retroperitoneal lymph node | 85 (45.7) |
Supradiaphragmatic lymph node | 95 (48.7) |
Other | 26 (13.8) |
Symptoms at presentation | |
None | 15 (10.4) |
Local | 70 (37.2) |
Metastatic site | 91 (48.4) |
Constitutional | 77 (41.0) |
Tumor thrombus | 67 (35.6) |
Based on biopsy.
CN, cytoreductive nephrectomy; ECOG, Eastern Cooperative Oncology Group; MDACC, M.D. Anderson Cancer Center; PS, performance status.